Shanghai 9th People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Huashan Hospital, Fudan University, Shanghai, China.
J Cosmet Dermatol. 2022 Oct;21(10):4288-4293. doi: 10.1111/jocd.14914. Epub 2022 Jun 1.
Restylane Defyne (HA , with lidocaine) has been shown to be effective and safe for facial augmentation including nasolabial folds (NLFs) in Caucasians. Incorporating lidocaine in injectable fillers has become a common practice that improves the patient's experience.
To evaluate efficacy and safety of HA compared to Restylane (HA , the gold standard HA filler) for correction of NLFs in a Chinese population.
In this 12-month, randomized, split-face, evaluator-blinded study of the efficacy and safety of treatment of NLFs with HA or HA , Chinese adults (n = 173) with moderate or severe wrinkle severity of both NLFs received treatment with HA on one NLF, and HA on the opposite NLF.
The primary objective was met: WSRS response rates at Month 6 (i.e., ≥1-grade improvement according to the blinded evaluator) were similar (72.9% and 72.8% for HA and HA , respectively). HA was non-inferior to HA ; the 95% CI for the difference in response rates was -5.7% to 5.5%. Likewise, products were effective and comparable in terms of reduced wrinkle severity of NLFs and improved Global Aesthetic Improvement Scale (GAIS) score (according to the blinded evaluator and subject) throughout the study. Both products were well-tolerated, and injection of the lidocaine-containing product (HA ) was less painful.
HA was non-inferior to HA for treatment of moderate-to-severe NLFs at 6 months post-treatment. Overall, the results from this study indicate that HA is safe and effective up to 12 months in a Chinese population.
丽瑅 Defyne(含利多卡因的 HA)已被证明在包括鼻唇沟(NLF)在内的面部填充方面是有效且安全的,适用于白种人。在注射用填充物中加入利多卡因已成为一种常见做法,可改善患者的体验。
评估 HA 相对于瑞蓝(HA,金标准 HA 填充剂)治疗中国人群 NLF 的疗效和安全性。
这是一项为期 12 个月、随机、双侧、观察者设盲的研究,评估 HA 治疗 NLF 的疗效和安全性,共纳入 173 例中重度 NLF 皱纹的中国成年人,他们双侧 NLF 中一侧接受 HA 治疗,另一侧接受 HA 治疗。
主要终点达到:6 个月时(根据盲法评估员,即 NLF 皱纹严重程度至少改善 1 级)的 WSRS 应答率相似(HA 为 72.9%,HA 为 72.8%)。HA 非劣效于 HA;应答率差值的 95%CI 为-5.7%至 5.5%。同样,两种产品在 NLF 皱纹严重程度减轻和改善全球美学改善量表(GAIS)评分(根据盲法评估员和受试者)方面均有效且相当,整个研究过程中均如此。两种产品均具有良好的耐受性,含利多卡因的产品(HA)注射时疼痛较轻。
HA 在治疗中重度 NLF 方面非劣效于 HA,治疗后 6 个月。总体而言,本研究结果表明,HA 在中国人中使用安全有效,最长可达 12 个月。